Varenicline for nicotine cessation in youth: A meta-analysis of randomized controlled trials addressing FDA labeling gaps in age and product use.

J Subst Use Addict TreatApr 25, 2026 (epub)
Clinical ResearchPsychiatryPediatrics

Joo Young Park, Seong-Joon Koh

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the effectiveness and safety of varenicline for nicotine cessation in young adults aged 12 to 26 years, analyzing data from five randomized controlled trials. The study found a statistically significant increase in smoking abstinence rates with varenicline compared to alternative interventions, with a relative risk of 1.99 (95% CI, 1.04-3.80).

Key findings

  • Varenicline significantly increased abstinence rates compared to alternative interventions (RR, 1.99; 95% CI, 1.04-3.80).
  • Abstinence rates with varenicline were also significantly higher compared to placebo (OR, 2.93; 95% CI, 1.01-8.49).
  • Safety profile of varenicline was comparable to placebo regarding treatment-emergent adverse events.

Why it matters

Understanding the effectiveness of varenicline in young adults is crucial as smoking cessation in this population can significantly reduce long-term health risks associated with nicotine use. This evidence may guide clinicians in making informed decisions about cessation strategies.

Source

PubMed · PMID 42044870

Published in J Subst Use Addict Treat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.